From owner-dros@hgmp.mrc.ac.uk Wed Jul 9 00:42:37 2003 Return-Path: X-Original-To: dros-outgoing Received: from localhost (localhost [127.0.0.1]) by mercury.hgmp.mrc.ac.uk (Postfix) with SMTP id 7AB787D3BC for ; Wed, 9 Jul 2003 00:42:37 +0100 (BST) X-Original-To: dros-list@hgmp.mrc.ac.uk Received: from localhost (localhost [127.0.0.1]) by mercury.hgmp.mrc.ac.uk (Postfix) with ESMTP id 7AEA37D172 for ; Wed, 9 Jul 2003 00:42:36 +0100 (BST) Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 6020) id 601C27D15B; Wed, 9 Jul 2003 00:42:27 +0100 (BST) X-Original-To: bionet-drosophila@net.bio.net Received: from localhost (localhost [127.0.0.1]) by mercury.hgmp.mrc.ac.uk (Postfix) with ESMTP id 10E527D1AD for ; Tue, 8 Jul 2003 09:54:34 +0100 (BST) Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 60001) id ECAD97D193; Tue, 8 Jul 2003 09:54:31 +0100 (BST) To: bionet-drosophila@net.bio.net From: laura.wood@researchandmarkets.com ("=?iso-8859-1?Q?Laura_Wood?=") Newsgroups: bionet.drosophila Subject: =?iso-8859-1?Q?Protein_Biochips_2003_?= Organization: BIOSCI/MRC Human Genome Mapping Project Resource Centre Message-ID: charset="iso-8859-1" X-Original-To: dros@net.bio.net X-Received: from localhost (localhost [127.0.0.1]) by mercury.hgmp.mrc.ac.uk (Postfix) with ESMTP id 769AE7D354 for ; Tue, 8 Jul 2003 09:54:30 +0100 (BST) X-Received: from www.researchandmarkets.com (unknown [62.17.245.34]) by mercury.hgmp.mrc.ac.uk (Postfix) with ESMTP id 9821C7D191 for ; Tue, 8 Jul 2003 09:54:25 +0100 (BST) X-Received: from mail pickup service by www.researchandmarkets.com with Microsoft SMTPSVC; Tue, 8 Jul 2003 09:46:41 +0100 X-To: "=?iso-8859-1?Q?dros@net=2Ebio=2Enet?=" X-Priority: 3 X-MSMail-Priority: Normal X-Mailer: JMail 4.3.1 by Dimac X-OriginalArrivalTime: 08 Jul 2003 08:46:41.0859 (UTC) FILETIME=[74014130:01C3452D] Date: Wed, 9 Jul 2003 00:42:27 +0100 (BST) Sender: owner-dros@hgmp.mrc.ac.uk Precedence: bulk I enclose details of our latest Protein Biochips Report. The protein biochip market is underserved, despite growing from $70 million in 2001 to $100 million in 2002. The Protein Biochips 2003 report presents a detailed market model and thorough analysis of the technologies and business strategies of 38 leading protein biochip companies. Protein Biochips 2003 projects that the market will grow to more than $400 million in 2007, a compound annual growth rate of more than 35%. Based on extensive primary and secondary research, including interviews with current and potential customers and with company representatives this research provides the foundation for a market model built on 30 interlinked sets of projections. For a complete index of this report click on http://www.researchandmarkets.com/reports/28460 At the highest level, the market is divided into three different applications: (1) Drug Target and Biomarker Discovery and Validation, (2) Drug Development, and (3) Clinical Trials and Diagnostics. The first application identifies and discovers targets and/or biomarkers and validates them through additional experimentation. The second application transforms the targets into potential therapeutics. The third application identifies and monitors disease states and drug responses. Each application is divided across two types of protein biochips: capture biochips and interaction biochips. - A capture biochip has immobilized capture agents that are used to capture target proteins, primarily for detection and quantification. - An interaction biochip has immobilized proteins or peptides that are used to identify function or to identify interactions with other proteins or with lipids or small molecules. Each type of biochip is divided into 5 subsections: price per biochip, number of biochips sold, price per hardware systems, number of hardware systems sold, and service revenue. The complete model reveals a multitude of information about the biochip market, including market size by application, by biochip type, by components, and by business model. The complete model also reveals unit sales and average pricing of capture and interaction biochips and their respective hardware systems. In addition to the detailed market model, Protein Biochips 2003 evaluates the strengths and weaknesses of each of the protein biochip makers, and assesses both opportunities and threats facing their products. Protein Biochips 2003 identifies the companies most likely to dominate specific market segments, as well as the companies most likely to play key supporting roles in moving technologies forward. For a complete index of this report click on http://www.researchandmarkets.com/reports/28460 Report Index: Chapter 1: Executive Summary 6 Introduction 7 Applications 8 Competitive Environment 9 State of the Market in 2003 10 - Demand 10 - Supply 11 - Competition 12 Market Model Methodology 13 Market Size 14 - Total 14 - By Application and Biochip Type 15 - By Components and Business Model 16 Chapter 2: Technology 17 Overview 18 - Biochip Type 18 - Biochip Assembly 19 - Biochip Usage 20 Biochip Components 21 - Immobilized (Non-Capture Agent) Proteins 21 - Capture Agents 23 - Surfaces 25 - Spotters 26 - Detection Methods 27 Alternative Technologies 29 Competing Technologies 30 Chapter 3: Applications 31 Applications 32 Protein Expression 33 Protein Function 34 Protein Interactions 35 Target/Biomarker Discovery 36 Target/Biomarker Validation 38 Drug Development 39 Clinical Trials/ Diagnostics 42 Chapter 4: Competitive Environment 44 Overview 45 Affibody AB 46 Archemix Corporation 47 Aspira Biosystems, Inc. 50 BD Biosciences Clontech 53 Biacore International AB 55 BioForce Nanosciences, Inc. 57 BioInvent International AB 60 Biosite Incorporated 62 Cambridge Antibody Technology Group plc 65 Ciphergen Biosystems, Inc. 67 CombiMatrix 70 Corning Incorporated Life Sciences 73 Discerna Ltd 75 Domantis Limited 77 GeneScan Europe AG 78 HTS Biosystems, Inc. 81 Hypromatrix, Inc. 83 Large Scale Biology Corporation 89 LumiCyte, Inc. 92 Molecular Staging Inc. 94 nanotype GmbH 96 NextGen Sciences Ltd. 99 Pepscan Systems BV 103 PerkinElmer Life Sciences 106 Phylos, Inc. 108 Procognia Ltd. 110 Prolinx, Inc. 112 Protagen AG 115 ProteinOne Inc. 118 Protiveris Inc. 120 Protometrix, Inc. 122 Randox Laboratories Ltd. 126 SomaLogic, Inc. 128 TeleChem International, Inc. 131 VBC-GENOMICS Bioscience Research GmbH 134 Zeptosens AG 136 Zyomyx, Inc. 139 Chapter 5: Market Model 143 State of the Market in 2003 144 - Demand 144 - Supply 145 - Competition 146 Total Market 147 - Companies 147 - Size 148 Market Model Methodology 149 Market Segmentation 150 Market Definitions 151 Market Inclusions 153 Market By Applications 154 - Drivers 154 - Companies 155 - Size and Shares 157 Market By Biochip Type 158 - Drivers 158 - Companies 159 - Size and Shares 160 Market By Components 161 - Drivers 161 - Size and Shares 162 Market By Business Model 163 - Drivers 163 - Companies 164 Biochip and Hardware Unit Sales 166 - Drivers 166 - Biochip Units and Shares 167 - Hardware Units and Shares 168 Pricing 169 - Drivers 169 - Biochips and Hardware 170 Appendix 1: Methodology 171 Market Model 172 Sources 173 - Primary Sources 173 - Knowledge Base 174 - Secondary Sources 175 Appendix 2: Glossary 176 Commonly Used Terms 177 Size and Shares 165 Jerini AG 85 Report Pricing: Hard Copy EUR 3,157 Electronic EUR 3,906 ORDERING - FOUR EASY WAYS TO PLACE YOUR ORDER: Order online: To order this report please click on http://www.researchandmarkets.com/reports/28460 Order via email: mailto:orders@researchandmarkets.com Order via fax-back form: Click on http://www.researchandmarkets.com/reports/28460 Fax to +353 14957318 Order via post: Click on http://www.researchandmarkets.com/reports/28460 Mail to Research and Markets Ltd., Guinness Centre, Taylors Lane, Dublin 8, Ireland Related Reports Available from Research & Markets Ltd: Protein Chips: The Race for High-Throughput Protein Analysis - http://www.researchandmarkets.com/reports/419 Cloning Technology: An Ongoing Battle between technologies versus ethical implication - http://www.researchandmarkets.com/reports/10805 Service and Support for Life Science Products: Creating Loyal Customers - http://www.researchandmarkets.com/reports/10745 Overcoming Formulations Challenges: Novel Techniques for Optimum Results - http://www.researchandmarkets.com/reports/4042 CNS Vaccines: The Risks and Benefits of Innovative Technologies - http://www.researchandmarkets.com/reports/4510 Emerging Pharmacological Tools in Clinical Neurology - http://www.researchandmarkets.com/reports/2355 Cancer Genomics: Evolving Terminology for Emerging Technologies - http://www.researchandmarkets.com/reports/10814 The US Bio-Chip Market for Pharmaceutical Drug Discovery: Technology, Strategic Alliance, Patent Dispute and Market Update, 2002 - http://www.researchandmarkets.com/reports/291 Marketing to Life Scientists: A Comparison of the Industrial and Academic Segments - http://www.researchandmarkets.com/reports/10746 Emerging Biotechnology Players: From Innovation to Realization - http://www.researchandmarkets.com/reports/29057 The Antivirals Outlook to 2007: Marketing opportunities by disease state, patient potential and product profile - http://www.researchandmarkets.com/reports/28368 Therapeutics Targeting ERB Family - http://www.researchandmarkets.com/reports/2356 InfoBase CD-ROM Directory of 12,000 Life Science Companies and Organizations - http://www.researchandmarkets.com/reports/17424 Prospects for Commercialization of Human Monoclonal Antibodies - http://www.researchandmarkets.com/reports/1929 Click on http://www.researchandmarkets.com for details. Thank you for your consideration. Kind Regards, Laura Wood Senior Manager Research and Markets Ltd laura.wood@researchandmarkets.com REPORT DATA SUMMARY: Protein Biochips 2003 Publisher Name: Select Biosciences Ltd Date Published: 05/05/03 Number of Pages: 180 Category: Biotechnology URL: www.researchandmarkets.com/reports/28460 Subscribe: Click on http://www.researchandmarkets.com/register.asp You can subscribe free for regular details on new research in your sector. If you no longer wish to receive our market research updates, please reply to this message with "Suppression Request" as the subject line, or email a blank email to suppressed@researchandmarkets.com or access our unsubscribe page at: http://www.researchandmarkets.com/unsubscribe.asp --- .